Navigen Announces Phase II NIH SBIR Award for the Advancement of Ebola Virus Therapy
Navigen, Inc., a Utah-based drug discovery and development company, has received an NIH award for $2.9 million to develop its anti-Ebola virus D-peptide. Navigen's compound targets a region of the Ebola virus that is 100% conserved and thus should be effective against all strains of virus. - March 24, 2015
Press Releases 1 - 1 of 1